Skip to main content
Premium Trial:

Request an Annual Quote

Takeshi Kawami, Paul Meister, Benjamin Reed, David Bell, David Fitzpatrick, Beatrice Perotti, Farnaz Khadem, Essam Sheta

Shimadzu Corp., this week named Takeshi Kawami president of its American subsidary, Shimadzu Scientific Instruments. Kawami, who has been with Shimadzu Corp., for 24 years, replaces Osamu Ando who had been SSI’s president for seven years. Ando is returning to Japan “for another assignment with Shimadzu,” a spokesman said. He did not provide further details.
Kawami, 50, will oversee sales and management functions at SSI, the company said in a statement. At Shimadzu Corp., he held several positions including sales manager, president of a Shimadzu sales subsidiary, and vice president of two merged sales subsidiaries.

Paul Meister said last week that he will not stand for reelection as chairman of the board of Thermo Fisher Scientific at the firm’s annual meeting on May 15. In anticipation of his retirement, Meister has already relinquished his position as chairman. The firm did not say whether any of the other directors have assumed his duties.
Thermo Fisher said it expects to identify a new director prior to its upcoming meeting.

Oxford Genome Sciences this week announced two personnel additions to its UK drug development and biomarker discovery operations, and two additions to its US preclinical group providing support to Oxford’s product portfolio development efforts.
In the UK, Benjamin Reed was named business development director of Oxford’s biomarker services division. He had previously been at Ciphergen Biosystems for six years. Also, David Bell was named head of mass spectrometry operations. He comes from GlaxoSmithKline where he worked for 18 years developing and applying MS methods for drug discovery and development processes.
In the US, David Fitzpatrick will lead the preclinical development team. He previously had been at Immunex and Amgen. Beatrice Perotti will be in charge of Oxford’s US business operations and lead the preclinical development program. Her past stints include Pfizer Central Research and Amgen.

Invitrogen appointed this week Farnaz Khadem director of corporate communications. She replaces Julie Ames who left the company to pursue other opportunities. Khadem has more than 15 years experience in strategic communications and public relations, Invitrogen said in a statement. Most recently, she was assistant director of media relations at the University of California, Irvine.

Power3 named Essam Sheta laboratory director for Clinical Laboratory Improvement Amendments approval this week. Sheta is also the company’s director of biochemistry.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.